Lynn Seely Blueprint Medicines Corp (BPMC) insider trading activity

Lynn Seely is Director of Blueprint Medicines Corp. Currently has a direct ownership of 0 shares of BPMC, which is worth approximately $0. The most recent transaction as insider was on Jul 17, 2025, when has been sold 13,254 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Lynn Seely Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 17 2025	SELL Disposition due to a tender of shares in a change of control transaction	-	13,254 Reduced 100.0%	0 Common Stock
Jul 17 2025	SELL Sale (or disposition) back to the issuer	-	3,902 Reduced 22.74%	13,254 Common Stock
Jun 18 2025	BUY Grant, award, or other acquisition	$499,924 $128.12 p/Share	3,902 Added 18.53%	17,156 Common Stock
Jun 12 2024	BUY Grant, award, or other acquisition	-	2,242 Added 14.47%	13,254 Common Stock
Jun 21 2023	BUY Grant, award, or other acquisition	-	2,600 Added 19.1%	11,012 Common Stock
Jun 21 2022	BUY Grant, award, or other acquisition	-	2,600 Added 23.61%	8,412 Common Stock
Jun 02 2021	BUY Grant, award, or other acquisition	-	2,250 Added 27.91%	5,812 Common Stock

Also insider at

LYEL

Lyell Immunopharma, Inc. Healthcare

President and CEO

Lynn Seely

Director

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Value

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC

Account